Acurx Pharmaceuticals LLC ACXP

NAS: ACXP | ISIN: US00510M1045   17/05/2024
2,250 USD (+4,17%)
(+4,17%)   17/05/2024
Grafiek Acurx Pharmaceuticals LLC Grafiek Acurx Pharmaceuticals LLC

Acurx Pharmaceuticals LLC in het nieuws

15 mei 2024 · Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection · Persbericht

15 mei 2024 · Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update · Persbericht

2 mei 2024 · Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference · Persbericht

25 april 2024 · Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference · Persbericht

23 april 2024 · Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update · Persbericht

18 maart 2024 · Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update · Persbericht

4 maart 2024 · Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update · Persbericht

27 februari 2024 · Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development · Persbericht

29 januari 2024 · Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients · Persbericht

23 januari 2024 · Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024 · Persbericht

Profiel Acurx Pharmaceuticals LLC

Werknemers: 3

Aandelen Acurx Pharmaceuticals LLC

Beurswaarde: 34,22 miljoen USD

Effecten: 15,84 miljoen

Beta: 0,47

Mijn selecties